Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1426389-04-9

Post Buying Request

1426389-04-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1426389-04-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1426389-04-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,2,6,3,8 and 9 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1426389-04:
(9*1)+(8*4)+(7*2)+(6*6)+(5*3)+(4*8)+(3*9)+(2*0)+(1*4)=169
169 % 10 = 9
So 1426389-04-9 is a valid CAS Registry Number.

1426389-04-9Downstream Products

1426389-04-9Relevant articles and documents

An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors

Pagano, Nicholas,Teriete, Peter,Mattmann, Margrith E.,Yang, Li,Snyder, Beth A.,Cai, Zhaohui,Heil, Marintha L.,Cosford, Nicholas D.P.

, p. 6248 - 6265 (2017/09/30)

Continuous flow (microfluidic) chemistry was employed to prepare a small focused library of dihydropyrimidinone (DHPM) derivatives. Compounds in this class have been reported to exhibit activity against the human immunodeficiency virus (HIV), but their molecular target had not been identified. We tested the initial set of DHPMs in phenotypic assays providing a hit (1i) that inhibited the replication of the human immunodeficiency virus HIV in cells. Flow chemistry-driven optimization of 1i led to the identification of HIV replication inhibitors such as 1l with cellular potency comparable with the clinical drug nevirapine (NVP). Mechanism of action (MOA) studies using cellular and biochemical assays coupled with 3D fingerprinting and in silico modeling demonstrated that these drug-like probe compounds exert their effects by inhibiting the viral reverse transcriptase polymerase (RT). This led to the design and synthesis of the novel DHPM 1at that inhibits the replication of drug resistant strains of HIV. Our work demonstrates that combining flow chemistry-driven analogue refinement with phenotypic assays, in silico modeling and MOA studies is a highly effective strategy for hit-to-lead optimization applicable to the discovery of future therapeutic agents.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1426389-04-9